Education
About Us
Working with TipRanks
Follow Us
Stayble Therapeutics AB (SE:STABL)
:STABL
STABL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $1.05
Previous CloseN/A
Volume514.07K
Average Volume (3M)561.36K
Market Cap
$23.79M
Enterprise ValueN/A
Total Cash (Recent Filing)kr2.19M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.60
Next Earnings
May 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding51,720,900
10 Day Avg. Volume148,210
30 Day Avg. Volume561,357
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
STABL FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was $0.22 and its highest was $1.05 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is $23.79M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
Stayble Therapeutics AB’s upcoming earnings report date is May 20, 2025 which is in 21 days.
How were Stayble Therapeutics AB’s earnings last quarter?
Stayble Therapeutics AB released its earnings results on Feb 25, 2025. The company reported -$0.069 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.069.
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 51,720,900 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Stayble Therapeutics AB reported an EPS of -$0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.198%.
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in SE:STABL
---
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.
---
Technical Analysis
---